Derux­te­can CAS 1599440-13-7

• Iden­ti­fi­ca­tion
• Prop­er­ties
• Safe­ty Data
• Spec­i­fi­ca­tions & Oth­er Information
• Links
• Quick Inquiry

Iden­ti­fi­ca­tion

CAS Number

1599440-13-7

Name

Derux­te­can

Syn­onyms

Glyci­namide, N-[6-(2,5-dihydro-2,5-dioxo-1H-pyrrol-1-yl)-1-oxohexyl]glycylglycyl-L-phenylalanyl-N-[[2-[[(1S,9S)-9-ethyl-5-fluoro-2,3,9,10,13,15-hexahydro-9-hydroxy-4-methyl-10,13-dioxo-1H,12H-benzo[de ]pyrano[3′,4′:6,7]indolizino[1,2-b]quinolin-1-yl]amino]-2-oxoethoxy]methyl]- [ACD/​Index Name]
N-[6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]glycylglycyl-L-phenylalanyl-N-[(2-{[(1S,9S)-9-ethyl-5-fluor-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6,7 ]indolizino[1,2-b]chinolin-1-yl]amino}-2-oxoethoxy)methyl]glycinamid [Ger­man] [ACD/IUPAC Name]
N-[6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]glycylglycyl-L-phénylalanyl-N-[(2-{[(1S,9S)-9-éthyl-5-fluoro-9-hydroxy-4-méthyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6, 7]indolizino[1,2-b]quinoléin-1-yl]amino}-2-oxoéthoxy)méthyl]glycinamide [French] [ACD/IUPAC Name]
N-[6-(2,5-Dioxo-2,5-dihydro-1H-pyrrol-1-yl)hexanoyl]glycylglycyl-L-phenylalanyl-N-[(2-{[(1S,9S)-9-ethyl-5-fluoro-9-hydroxy-4-methyl-10,13-dioxo-2,3,9,10,13,15-hexahydro-1H,12H-benzo[de]pyrano[3′,4′:6, 7]indolizino[1,2-b]quinolin-1-yl]amino}-2-oxoethoxy)methyl]glycinamide [ACD/IUPAC Name]
1599440-13-7 [RN]
6-(2,5-dioxopyrrol-1-yl)-N-[2-[[2-[[(2S)-1-[[2-[[2-[[(10S,23S)-10-ethyl-18-fluoro-10-hydroxy-19-methyl-5,9-dioxo-8-oxa-4,15-diazahexacyclo[14.7.1.02,14.04,13.06,11.020,24]tetracosa-1,6(11),12,14,16,18,20(24)-heptaen-23-yl]amino]-2-oxoethoxy]methylamino]-2-oxoethyl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-2-oxoethyl]amino]-2-oxoethyl]hexanamide
Derux­te­can
Derux­te­can Analog

SMILES

CC[C@@]1(c2cc-3n(c(=O)c2COC1=O)Cc4c3nc5cc(c(c6c5c4[C@H](CC6)NC(=O)COC­NC(=O)CNC(=O)[C@H](Cc7ccccc7)NC(=O)CNC(=O)CNC(=O)CCCCCN8C(=O)C=CC8=O)C)F)O

Std­InChI

InChI=1S/C52H56FN9O13/c1-3-52(73)33-19-38-48-31(24-62(38)50(71)32(33)25-75-51(52)72)47-35(14-13-30-28(2)34(53)20-36(60-48)46(30)47)58-43(67)26-74-27-57-41(65)22-56-49(70)37(18-29-10-6-4-7-11-29)59-42(66)23-55-40(64)21-54-39(63)12-8-5-9-17-61-44(68)15-16-45(61)69/h4,6-7,10-11,15-16,19-20,35,37,73H,3,5,8-9,12-14,17-18,21-27H2,1-2H3,(H,54,63)(H,55,64)(H,56,70)(H,57,65)(H,58,67)(H,59,66)/t35-,37-,52-/m0/s1

Std­InChIKey

WXN­SCLIZKHLNSG-MCZRLC­S­D­SA-N

Mol­e­c­u­lar Formula

C₅₂H₅₆FN₉O₁₃

Mol­e­c­u­lar Weight

1034.052

MDL Number

MFCD31657445

Prop­er­ties

Appear­ance

Light yel­low powder

Safe­ty Data

Sym­bol

GHS06

Sig­nal Word

Dan­ger

Haz­ard statements

Pre­cau­tion­ary Statements

RIDADR 

NONH for all modes of transport

WGK Germany

3

Spec­i­fi­ca­tions and Oth­er Infor­ma­tion of Our Derux­te­can CAS 1599440-13-7

Iden­ti­fi­ca­tion Methods

HNMR, HPLC

Puri­ty

99% min

Total Impu­ri­ties

1%max

Shelf Life

2 years

Stor­age

Under room tem­per­a­ture away from light

Pro­duc­tiv­i­ty

Always hold the stock of kilograms

Known Appli­ca­tion

Trastuzum­ab-dru­ti­­can (DS-8201) is an anti­body drug con­ju­gate (ADC) com­posed of a human­ized anti-HER2 mon­o­clon­al anti­body (Trastuzum­ab), a cleav­able tetrapep­tide-based link­er and a cyto­tox­ic pep­tide. Chem­i­cal­book iso­merase I inhibitor (DXd), which pre­vents can­cer cells from repli­cat­ing DNA, lead­ing to can­cer cell death. Trastuzum­ab-derute­­can is approved for the treat­ment of patients with HER2-pos­i­­tive metasta­t­ic breast and gas­tric cancer.

Links

This prod­uct is devel­oped by our R&D com­pa­ny Cam­ing Phar­ma­ceu­ti­cal Ltd (https://​www​.cam​ing​.com/).

Quick Inquiry

Fill out our inquiry form and one of our experts will be in touch with you shortly.